search
Back to results

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Primary Purpose

Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Sponsored by
Astellas Pharma Europe B.V.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lower Urinary Tract Symptoms focused on measuring Vesomni, Solifenacin succinate, EC905, Tamsulosin hydrochloride OCAS, Treatment, Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Completion of 12 weeks double-blind treatment in Study 905-CL-055

Exclusion Criteria:

  • Any significant PVR volume (>150 mL)

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Total Group

Arm Description

Participants who received at least one dose of open-label fixed dose combination (FDC) treatment

Outcomes

Primary Outcome Measures

Number of Participants With Adverse Events (AEs)
Safety is monitored by collecting AEs, which include abnormal lab parameters, vital signs or ECG data if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study drug or was clinically significant. A serious AE (SAE) was an AE resulting in death, persistent or significant disability/incapacity or congenital anomaly/birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs were assessed by the Investigator for intensity (mild-no disruption of normal daily activities, moderate-affected normal daily activities or severe-inability to perform daily activities) and for causal relationship to study drug. A treatment-emergent adverse event (TEAE) was defined as an AE that occurred after the intake of first dose of double-blind study drug (if on FDC in 905-CL-055) or after first open-label dose until 30 days after the last dose of open-label study drug (in 905-CL-057).
Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
PVR volume is the volume of urine retained after voiding. PVR volume was assessed by ultrasonography or bladder scan.
Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
Qmax during a micturition (urination) was recorded using uroflowmetry.
Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
Qmean during a micturition (urination) was recorded using uroflowmetry.
Change From Baseline to End of Treatment in Total International Prostate Symptom Score (IPSS)
The International Prostate Symptom Score (IPSS) is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: Incomplete emptying of the bladder Intermittency Weak stream Hesitancy Frequency Urgency Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom. Total score can range from 0 to 35 (mildly symptomatic to severely symptomatic).
Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS) (Previously Known as Total Urgency Score [TUS])
The Patient Perception of the Intensity of Urgency Scale (PPIUS) is a validated scale completed as part of the micturition diary. For each micturition and/or incontinence episode, the participant rated the degree of associated urgency according to the following 5-point categorical scale: 0. No urgency; 1. Mild urgency; 2. Moderate urgency; 3. Severe urgency; 4. Urgency incontinence TUS/TUFS was calculated as the sum of the PPIUS gradings from the 3-day diary divided by the number of days on which urgency grading was recorded. Higher scores indicate more severe urgency.

Secondary Outcome Measures

Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
A micturition is any voluntary urination, excluding episodes of incontinence only.The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition
A micturition is any voluntary urination, excluding episodes of incontinence only. The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition
A micturition is any voluntary urination, excluding episodes of incontinence only. The maximum volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours
An urgency episode is defined as an episode of strong desire to void accompanied by fear of leakage or pain. The mean number of urgency episodes with PPIUS grade 3 (Severe urgency) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
An urgency incontinence episode is defined as an episode with any involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes with PPIUS grade 3 (Severe incontinence) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
An incontinence episode is defined as an episode with any involuntary loss of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours
A nocturia episode is defined as waking up at night to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours
The mean number of pads per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Change From Baseline to End of Treatment in IPSS Voiding Score
The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 voiding questions (incomplete emptying of the bladder, intermittency, weak stream, hesitancy) and ranges from 0 to 20 (mildly symptomatic to severely symptomatic).
Change From Baseline to End of Treatment in IPSS Storage Score
The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 storage questions (frequency,urgency and nocturia) and ranges from 0 to 15 (mildly symptomatic to severely symptomatic).
Change From Baseline to End of Treatment in IPSS Quality of Life (QoL) Score
The QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The answers ranged from 0 to 6 (delighted to terrible).
Change From Baseline to End of Treatment in Individual IPSS Scores
The IPSS is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: Incomplete emptying of the bladder Intermittency Weak stream Hesitancy Frequency Urgency Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom.
Change From Baseline to End of Treatment in Symptom Bother Score
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The Symptom Bother portion consists of an 8-item scale scored from 1 to 6.The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from baseline indicates an improvement.
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Coping Score
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Coping score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Concern Score
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Concern score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Sleep Score
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Sleep score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Social Score
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Social score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Total Score
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Total score is calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Number of OAB-q Responders Based on Health-related Quality of Life: Total Score
A OAB-q responder was defined as a participant with an improvement from baseline in HRQoL subscale total score ≥ 10.
Change From Baseline to End of Treatment in EQ-5D Mobility Score
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = confined to bed).
Change From Baseline to End of Treatment in EQ-5D Self-care Score
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to wash/dress).
Change From Baseline to End of Treatment in EQ-5D Usual Activities Score
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to perform usual activities).
Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no pain, 2= moderate pain, 3 = extreme pain).
Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= not anxious, 2= moderately anxious, 3 = extremely anxious).
Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score
Visual Analogue Scale (VAS) is part of the EQ-5D questionnaire. The VAS is self-rated by the participant ranging from 0 to 100 (worst imaginable health state to best imaginable health state).

Full Information

First Posted
November 24, 2009
Last Updated
November 20, 2017
Sponsor
Astellas Pharma Europe B.V.
search

1. Study Identification

Unique Protocol Identification Number
NCT01021332
Brief Title
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Acronym
Neptune II
Official Title
An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
April 26, 2010 (Actual)
Primary Completion Date
December 14, 2011 (Actual)
Study Completion Date
December 14, 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Astellas Pharma Europe B.V.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.
Detailed Description
This is an open-label extension study following the double blind 905-CL-055 study

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Keywords
Vesomni, Solifenacin succinate, EC905, Tamsulosin hydrochloride OCAS, Treatment, Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1067 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Total Group
Arm Type
Experimental
Arm Description
Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
Intervention Type
Drug
Intervention Name(s)
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
Other Intervention Name(s)
EC905, Vesomni
Intervention Description
oral
Intervention Type
Drug
Intervention Name(s)
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Other Intervention Name(s)
EC905
Intervention Description
oral
Primary Outcome Measure Information:
Title
Number of Participants With Adverse Events (AEs)
Description
Safety is monitored by collecting AEs, which include abnormal lab parameters, vital signs or ECG data if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study drug or was clinically significant. A serious AE (SAE) was an AE resulting in death, persistent or significant disability/incapacity or congenital anomaly/birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs were assessed by the Investigator for intensity (mild-no disruption of normal daily activities, moderate-affected normal daily activities or severe-inability to perform daily activities) and for causal relationship to study drug. A treatment-emergent adverse event (TEAE) was defined as an AE that occurred after the intake of first dose of double-blind study drug (if on FDC in 905-CL-055) or after first open-label dose until 30 days after the last dose of open-label study drug (in 905-CL-057).
Time Frame
From first dose of double-blind study drug (if on FDC in 905-CL-055) or first open-label dose up to 30 days after last dose of open-label study drug (in 905-CL-057) (up to 56 weeks)
Title
Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
Description
PVR volume is the volume of urine retained after voiding. PVR volume was assessed by ultrasonography or bladder scan.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
Description
Qmax during a micturition (urination) was recorded using uroflowmetry.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
Description
Qmean during a micturition (urination) was recorded using uroflowmetry.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Total International Prostate Symptom Score (IPSS)
Description
The International Prostate Symptom Score (IPSS) is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: Incomplete emptying of the bladder Intermittency Weak stream Hesitancy Frequency Urgency Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom. Total score can range from 0 to 35 (mildly symptomatic to severely symptomatic).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS) (Previously Known as Total Urgency Score [TUS])
Description
The Patient Perception of the Intensity of Urgency Scale (PPIUS) is a validated scale completed as part of the micturition diary. For each micturition and/or incontinence episode, the participant rated the degree of associated urgency according to the following 5-point categorical scale: 0. No urgency; 1. Mild urgency; 2. Moderate urgency; 3. Severe urgency; 4. Urgency incontinence TUS/TUFS was calculated as the sum of the PPIUS gradings from the 3-day diary divided by the number of days on which urgency grading was recorded. Higher scores indicate more severe urgency.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Secondary Outcome Measure Information:
Title
Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
Description
A micturition is any voluntary urination, excluding episodes of incontinence only.The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition
Description
A micturition is any voluntary urination, excluding episodes of incontinence only. The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition
Description
A micturition is any voluntary urination, excluding episodes of incontinence only. The maximum volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours
Description
An urgency episode is defined as an episode of strong desire to void accompanied by fear of leakage or pain. The mean number of urgency episodes with PPIUS grade 3 (Severe urgency) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
Description
An urgency incontinence episode is defined as an episode with any involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes with PPIUS grade 3 (Severe incontinence) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
Description
An incontinence episode is defined as an episode with any involuntary loss of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours
Description
A nocturia episode is defined as waking up at night to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours
Description
The mean number of pads per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in IPSS Voiding Score
Description
The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 voiding questions (incomplete emptying of the bladder, intermittency, weak stream, hesitancy) and ranges from 0 to 20 (mildly symptomatic to severely symptomatic).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in IPSS Storage Score
Description
The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 storage questions (frequency,urgency and nocturia) and ranges from 0 to 15 (mildly symptomatic to severely symptomatic).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in IPSS Quality of Life (QoL) Score
Description
The QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The answers ranged from 0 to 6 (delighted to terrible).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Individual IPSS Scores
Description
The IPSS is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: Incomplete emptying of the bladder Intermittency Weak stream Hesitancy Frequency Urgency Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Symptom Bother Score
Description
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The Symptom Bother portion consists of an 8-item scale scored from 1 to 6.The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from baseline indicates an improvement.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Coping Score
Description
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Coping score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Concern Score
Description
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Concern score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Sleep Score
Description
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Sleep score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Social Score
Description
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Social score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Total Score
Description
The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping concern sleep social interaction Total score is calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Number of OAB-q Responders Based on Health-related Quality of Life: Total Score
Description
A OAB-q responder was defined as a participant with an improvement from baseline in HRQoL subscale total score ≥ 10.
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in EQ-5D Mobility Score
Description
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = confined to bed).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in EQ-5D Self-care Score
Description
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to wash/dress).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in EQ-5D Usual Activities Score
Description
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to perform usual activities).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score
Description
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= no pain, 2= moderate pain, 3 = extreme pain).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score
Description
The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: mobility self-care usual activity pain/discomfort anxiety/depression Each domain has 3 response levels (1= not anxious, 2= moderately anxious, 3 = extremely anxious).
Time Frame
Baseline and up to 52 weeks of FDC treatment
Title
Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score
Description
Visual Analogue Scale (VAS) is part of the EQ-5D questionnaire. The VAS is self-rated by the participant ranging from 0 to 100 (worst imaginable health state to best imaginable health state).
Time Frame
Baseline and up to 52 weeks of FDC treatment

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Completion of 12 weeks double-blind treatment in Study 905-CL-055 Exclusion Criteria: Any significant PVR volume (>150 mL)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Use Central Contact
Organizational Affiliation
Astellas Pharma Global Development
Official's Role
Study Chair
Facility Information:
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
City
Vienna
ZIP/Postal Code
1090
Country
Austria
City
Minsk
ZIP/Postal Code
220036
Country
Belarus
City
Minsk
ZIP/Postal Code
220119
Country
Belarus
City
Minsk
ZIP/Postal Code
223040
Country
Belarus
City
Antwerp
ZIP/Postal Code
2020
Country
Belgium
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
City
Gent
ZIP/Postal Code
9000
Country
Belgium
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
City
Liege 1
ZIP/Postal Code
4000
Country
Belgium
City
Hradec Kralove
ZIP/Postal Code
500 02
Country
Czechia
City
Ostrava
ZIP/Postal Code
700 30
Country
Czechia
City
Plzen
ZIP/Postal Code
301 24
Country
Czechia
City
Roudnice nad Labem
ZIP/Postal Code
413 01
Country
Czechia
City
Uherske Hradiste
ZIP/Postal Code
686 08
Country
Czechia
City
Usti nad Labem
ZIP/Postal Code
400 01
Country
Czechia
City
Zd'ar nad Sazavou
ZIP/Postal Code
591 01
Country
Czechia
City
Colmar Cedex
ZIP/Postal Code
68024
Country
France
City
Montlucon
ZIP/Postal Code
03100
Country
France
City
Orleans cedex 2
ZIP/Postal Code
45067
Country
France
City
Paris Cedex 10
ZIP/Postal Code
75020
Country
France
City
Paris
ZIP/Postal Code
75010
Country
France
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
City
Bautzen
ZIP/Postal Code
02625
Country
Germany
City
Frankfurt
ZIP/Postal Code
65933
Country
Germany
City
Ganderkesee
ZIP/Postal Code
27777
Country
Germany
City
Hagenow
ZIP/Postal Code
19230
Country
Germany
City
Halle Saale
ZIP/Postal Code
06132
Country
Germany
City
Hamburg
ZIP/Postal Code
20253
Country
Germany
City
Henningsdorf
ZIP/Postal Code
16761
Country
Germany
City
Hettstedt
ZIP/Postal Code
06333
Country
Germany
City
Koblenz
ZIP/Postal Code
56068
Country
Germany
City
Leipzig
ZIP/Postal Code
04105
Country
Germany
City
Leipzig
ZIP/Postal Code
04109
Country
Germany
City
Lutherstadt Eisleben
ZIP/Postal Code
06295
Country
Germany
City
Neustadt in Sachsen
ZIP/Postal Code
01844
Country
Germany
City
Radebeul
ZIP/Postal Code
01445
Country
Germany
City
Sachsen
ZIP/Postal Code
06526
Country
Germany
City
Trier
ZIP/Postal Code
54290
Country
Germany
City
Uetersen
ZIP/Postal Code
25436
Country
Germany
City
Avellino
ZIP/Postal Code
83100
Country
Italy
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
City
Palermo
ZIP/Postal Code
90146
Country
Italy
City
Treviglio
ZIP/Postal Code
24047
Country
Italy
City
Amsterdam
ZIP/Postal Code
100 AD
Country
Netherlands
City
Apeldoorn
ZIP/Postal Code
7334 DZ
Country
Netherlands
City
Doetinchem
ZIP/Postal Code
7009 BL
Country
Netherlands
City
Maastricht
ZIP/Postal Code
6229 HX
Country
Netherlands
City
Sneek
ZIP/Postal Code
8600 BA
Country
Netherlands
City
Tilburg
ZIP/Postal Code
5022 GC
Country
Netherlands
City
Winterswijk
ZIP/Postal Code
7101 BN
Country
Netherlands
City
Bielsko-Biala
ZIP/Postal Code
43-300
Country
Poland
City
Bydgoszcz
ZIP/Postal Code
85-094
Country
Poland
City
Krakow
ZIP/Postal Code
31-530
Country
Poland
City
Pulawy
ZIP/Postal Code
24-100
Country
Poland
City
Warsaw
ZIP/Postal Code
02-005
Country
Poland
City
Wiecbork
ZIP/Postal Code
89-410
Country
Poland
City
Nitra
ZIP/Postal Code
949 01
Country
Slovakia
City
Piestany
ZIP/Postal Code
921 02
Country
Slovakia
City
Presov
ZIP/Postal Code
080 01
Country
Slovakia
City
Skalica
ZIP/Postal Code
909 82
Country
Slovakia
City
Trencin
ZIP/Postal Code
911 01
Country
Slovakia
City
Cardiff
ZIP/Postal Code
CF14 5GJ
Country
United Kingdom
City
Chorley
ZIP/Postal Code
PR7 7NA
Country
United Kingdom
City
Liverpool
ZIP/Postal Code
L22 0LG
Country
United Kingdom
City
Northwood
ZIP/Postal Code
HA6 2RN
Country
United Kingdom
City
Oxford
ZIP/Postal Code
OX3 7LJ
Country
United Kingdom
City
Reading
ZIP/Postal Code
RG2 7AG
Country
United Kingdom
City
Sheffield
ZIP/Postal Code
S10 2JF
Country
United Kingdom
City
Taunton
ZIP/Postal Code
TA1 5DA
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.
Links:
URL
https://www.astellasclinicalstudyresults.com/study.aspx?ID=39
Description
Link to results on Astellas Clinical Study Results website

Learn more about this trial

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms

We'll reach out to this number within 24 hrs